Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARC-520 + tenofovir
- Development stage
- Unknown
- Lead developer
- Arrowhead Pharmaceuticals
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Oral
01
Overview
ARC-520 + tenofovir is a combination regimen used in the treatment of chronic hepatitis B virus (HBV) infection. ARC-520 is an RNA interference (RNAi) therapeutic comprising small interfering RNAs (siRNAs) that target HBV viral transcripts derived from covalently closed circular DNA (cccDNA), resulting in the reduction of hepatitis B surface antigen (HBsAg) and other viral antigens. Tenofovir is a nucleoside analogue reverse transcriptase inhibitor (NUC) that inhibits HBV DNA polymerase, thereby suppressing HBV DNA replication. In clinical studies, administration of ARC-520 in combination with tenofovir led to significant reductions in HBsAg and HBeAg levels and sustained suppression of HBV DNA. The combination regimen was generally well tolerated with no severe safety signals observed[3][4][5][7][8][9].
- Other names
- ARC-520 plus tenofovirARC520 plus tenofovirARC 520 plus tenofovirARC-520 in combination with tenofovirARC520 in combination with tenofovirARC 520 in combination with tenofovir
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on ARC-520 + tenofovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARC-520 + tenofovir.